Non-Small Cell Lung Cancer Coverage from Every Angle

WCLC 2018: Entrectinib in ROS1-Positive NSCLC

By: Susan Reckling
Posted: Wednesday, September 26, 2018

According to early-phase research presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) in Toronto (Abstract OA02.01), entrectinib demonstrated a response rate of 77% in patients with locally advanced or metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC). In addition, this selective inhibitor of ROS1 showed intracranial activity in many patients with baseline central nervous system (CNS) disease.

“Previous drugs targeting ROS1 such as crizotinib have poor CNS penetration and therefore can allow disease progression in the brain even before the cancer becomes resistant to the drug,” stated Robert C. Doebele, MD, PhD, Director of the University of Colorado Cancer Center Thoracic Oncology Research Initiative and principal study investigator, in a University of Colorado Cancer Center press release. “We are hopeful that entrectinib will help us control many cases of ROS1-positive cancer in both the body and the brain.”

Of the 53 patients with treatment-naive disease who were evaluable for efficacy, the objective response rate was 77.4%, with 3 patients having a complete response. On blinded independent central review, the duration of response was 24.6 months, and the median progression-free survival was 26.3 months. Furthermore, the intracranial objective response rate was 55%, with a median intracranial duration of response of 12.9 months.

As for toxicity, most treatment-related adverse events were grade 1 or 2 in the 355 patients evaluated for overall safety. Dose reduction was required in 27.3% of patients, and 3.9% discontinued treatment because of side effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.